Clinical Trials Logo

Stable Coronary Disease clinical trials

View clinical trials related to Stable Coronary Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05152888 Recruiting - Clinical trials for Stable Coronary Disease

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

EMPOWER
Start date: March 3, 2022
Phase: Phase 4
Study type: Interventional

The study protocol is a single-arm, open label pilot study designed to evaluate the impact of PCSK-9 inhibition on coronary blood flow in patients with stable coronary artery disease. Patients with stable coronary artery disease will be recruited from the BWH Cardiovascular Medicine clinic and/or from the BWH Nuclear Cardiology Laboratory. A target sample size of 50 participants will undergo imaging with N-13 ammonia or Rubidium-82 positron emission tomography (PET) and coronary computed tomography angiography (CCTA) before and after 12 months of PCSK-9 inhibition with Evolocumab to assess changes in myocardial blood flow, and plaque volume. To help account for physiological changes that may occur in myocardial blood flow and inflammatory biomarkers during the study period, we will also recruit a parallel control group of stable CAD patients who will undergo similar baseline and 12-month imaging and biomarker assessment. We plan to recruit 15 patients in the parallel control group.